```
     (FILE 'HOME' ENTERED AT 22:49:43 ON 09 NOV 2008)

     FILE 'REGISTRY' ENTERED AT 22:51:32 ON 09 NOV 2008
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS SAM
L3           8 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 22:52:48 ON 09 NOV 2008

=> s L3
L4           6 L3

=> d L4 1-6 TI ABS IBIB HITSTR

L4   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Pharmaceutical compositions based on anticholinergics and additional
     active ingredients
AB   A pharmaceutical compn. comprising an anticholinergic and at least one
     addnl. active ingredient selected from among corticosteroids, dopamine
     agonists, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists,
     antihistamines, and EGFR-kinase inhibitors, processes for prepg. them and
     their use in the treatment of respiratory diseases.  Among a no. of
     compds. prepd. was N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-[4-[(3-
     hydroxypropyl)methylamino]piperidin-1-yl]-N-methyl-2-phenylacetamide.
     Inhalable powders include a formulation contg. tiotropium bromide,
     budesonide, and lactose.
ACCESSION NUMBER:         2005:586215  CAPLUS
DOCUMENT NUMBER:          143:120526
TITLE:                    Pharmaceutical compositions based on anticholinergics
                          and additional active ingredients
INVENTOR(S):              Pairet, Michel; Pieper, Michael P.; Meade, Christopher
                          John Montague; Reichl, Richard; Schmelzer, Christel;
                          Jung, Birgit
PATENT ASSIGNEE(S):       Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany
SOURCE:                   U.S. Pat. Appl. Publ., 50 pp., Cont.-in-part of U.S.
                          Ser. No. 824,391.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   19
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
     US 20050148562       A1    20050707    US 2004-6940            20041208
     DE 10062712          A1    20020620    DE 2000-10062712        20001215
     DE 10063957          A1    20020627    DE 2000-10063957        20001220
     DE 10110772          A1    20020912    DE 2001-10110772        20010307
     DE 10111058          A1    20020912    DE 2001-10111058        20010308
     DE 10113366          A1    20020926    DE 2001-10113366        20010320
     DE 10138272          A1    20030227    DE 2001-10138272        20010810
     US 20020151541       A1    20021017    US 2001-7182            20011019
     US 20020183292       A1    20021205    US 2001-86145           20011019
     CA 2614631           A1    20020510    CA 2001-2614631         20011023
     US 20020137764       A1    20020926    US 2001-40196           20011025
     US 20020122773       A1    20020905    US 2001-27662           20011220
     DE 10206505          A1    20030828    DE 2002-10206505        20020216
     US 20020169181       A1    20021114    US 2002-92116           20020306
     US 6620438           B2    20030916
     US 20020193393       A1    20021219    US 2002-93240           20020307
```

US	20020183347	A1	20021205	US 2002-100659		20020318
US	6608054	B2	20030819			
US	20030158196	A1	20030821	US 2003-360064		20030207
US	20030181478	A1	20030925	US 2003-395777		20030324
US	6890517	B2	20050510			
US	20030203925	A1	20031030	US 2003-413065		20030414
US	20030212075	A1	20031113	US 2003-419358		20030421
US	6696042	B2	20040224			
US	20040024007	A1	20040205	US 2003-613783		20030703
US	20040151770	A1	20040805	US 2004-763894		20040123
US	20040161386	A1	20040819	US 2004-775901		20040210
US	20040176338	A1	20040909	US 2004-776757		20040211
US	20040192675	A1	20040930	US 2004-824391		20040414
US	20050147564	A1	20050707	US 2005-68134		20050228
AU	2008202554	A1	20080703	AU 2008-202554		20080610
PRIORITY APPLN. INFO.:				DE 2000-10054042	A	20001031
				US 2000-253613P	P	20001128
				DE 2000-10062712	A	20001215
				DE 2000-10063957	A	20001220
				US 2000-257220P	P	20001221
				US 2000-257221P	P	20001221
				DE 2001-10110772	A	20010307
				DE 2001-10111058	A	20010308
				DE 2001-10113366	A	20010320
				US 2001-281653P	P	20010405
				US 2001-281857P	P	20010405
				US 2001-281874P	P	20010405
				DE 2001-10138272	A	20010810
				US 2001-314599P	P	20010824
				US 2001-7182	B1	20011019
				US 2001-86145	B1	20011019
				US 2001-27662	B1	20011220
				DE 2002-10206505	A	20020216
				US 2002-92116	A1	20020306
				US 2002-93240	B1	20020307
				US 2002-100659	A1	20020318
				US 2002-369213P	P	20020401
				US 2003-360064	A2	20030207
				US 2003-413065	B2	20030414
				US 2003-419358	A1	20030421
				US 2003-613783	A2	20030703
				US 2004-763894	A2	20040123
				US 2004-775901	A2	20040210
				US 2004-776757	A2	20040211
				US 2004-824391	A2	20040414
				CA 2001-2436540	A3	20011023
				US 2001-40196	B1	20011025
				US 2003-395777	A1	20030324
				AU 2006-202723	A3	20060626

OTHER SOURCE(S): MARPAT 143:120526

IT 415917-07-6P 457910-79-1P 502422-75-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. based on anticholinergics and addnl. active ingredients)

RN 415917-07-6 CAPLUS

CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 457910-79-1 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(2-hydroxyethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl- (CA INDEX NAME)



RN 502422-75-5 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl-, (2E)-2-butenedioate (2:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 415916-92-6
CMF C28 H35 F6 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

TI Pharmaceutical compositions comprising novel anticholinergic agents and NK1-receptor antagonists for the treatment of respiratory tract diseases

AB The invention relates to novel pharmaceutical compns. comprising novel anticholinergic agents and NK1-receptor antagonists, method for prodn. and use thereof in the treatment of respiratory diseases. Thus an inhalation capsule contained (microgram/capsule): 2,2-Diphenylpropionic acid scopine ester methobromide 200; N-[2-(3,5-Bis-trifluoromethylphenyl)-ethyl]-2-{4-[(3-hydroxypropyl)methylamino]piperidin-1-yl}-N-methyl-2-phenylacetamide 150; lactose 12150.

ACCESSION NUMBER: 2004:41273 CAPLUS
DOCUMENT NUMBER: 140:99643
TITLE: Pharmaceutical compositions comprising novel anticholinergic agents and NK1-receptor antagonists for the treatment of respiratory tract diseases
INVENTOR(S): Pairet, Michel; Meade, Christopher John Montague; Pieper, Michael P.
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004724	A1	20040115	WO 2003-EP6667	20030625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10230750	A1	20040122	DE 2002-10230750	20020709
CA 2491451	A1	20040115	CA 2003-2491451	20030625
AU 2003242754	A1	20040123	AU 2003-242754	20030625
EP 1521580	A1	20050413	EP 2003-762508	20030625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005532378	T	20051027	JP 2004-518565	20030625
US 20040048886	A1	20040311	US 2003-614362	20030707

PRIORITY APPLN. INFO.: DE 2002-10230750 A 20020709
US 2002-407758P P 20020903
WO 2003-EP6667 W 20030625

OTHER SOURCE(S): MARPAT 140:99643
IT 415916-92-6
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical compns. comprising anticholinergic agents and

NK1-receptor antagonists for treatment of respiratory tract diseases)

RN 415916-92-6 CAPLUS

CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl- (CA INDEX NAME)



IT 457910-81-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising anticholinergic agents and NK1-receptor antagonists for treatment of respiratory tract diseases)

RN 457910-81-5 CAPLUS

CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

TI Method using NK1 receptor antagonists for the treatment or prevention of atopic dermatitis

GI



I

AB The invention provides a method for the treatment or prevention of atopic dermatitis, which comprises the administration of an effective amt. of an NK1 receptor antagonist to a patient in need of such treatment, wherein the NK1 receptor antagonist is effective in inhibiting substance P-induced scratching in mice. Compds. of the invention include e.g. I. Prepn. of selected compds. is described.

ACCESSION NUMBER: 2003:238299 CAPLUS
DOCUMENT NUMBER: 138:248551
TITLE: Method using NK1 receptor antagonists for the treatment or prevention of atopic dermatitis
INVENTOR(S): Komune, Kunihiko; Ohmura, Tsuyoshi; Satoh, Hisashi
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1295599	A1	20030326	EP 2001-122730	20010921
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030100565	A1	20030529	US 2002-236824	20020906
WO 2003026658	A1	20030403	WO 2002-EP10502	20020919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002333858	A1	20030407	AU 2002-333858	20020919

PRIORITY APPLN. INFO.:
EP 2001-122730 A 20010921
US 2001-338416P P 20011115
WO 2002-EP10502 W 20020919

OTHER SOURCE(S): MARPAT 138:248551

IT 415917-07-6P 415917-12-3P 502422-75-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(NK1 receptor antagonists for treatment or prevention of atopic dermatitis)

RN 415917-07-6 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 415917-12-3 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 502422-75-5 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl-, (2E)-2-butenedioate (2:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 415916-92-6
CMF C28 H35 F6 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

TI Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists for the treatment of respiratory tract diseases

AB The invention discloses pharmaceutical compns. based on anticholinergics and NK1-receptor antagonists, processes for prepg. them, and their use in the treatment of respiratory tract diseases. Prepn. of selected compds. is included.

ACCESSION NUMBER: 2002:869585 CAPLUS
DOCUMENT NUMBER: 137:346202
TITLE: Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists for the treatment of respiratory tract diseases
INVENTOR(S): Pairet, Michel; Pieper, Michael P.; Meade, Christopher J. M.
PATENT ASSIGNEE(S): Germany
SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U. S. Provisional Ser. NO. 281,653.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020169181	A1	20021114	US 2002-92116	20020306
US 6620438	B2	20030916		
DE 10111058	A1	20020912	DE 2001-10111058	20010308
US 20030212075	A1	20031113	US 2003-419358	20030421
US 6696042	B2	20040224		
US 20040151770	A1	20040805	US 2004-763894	20040123
US 20050148562	A1	20050707	US 2004-6940	20041208
AU 2008202554	A1	20080703	AU 2008-202554	20080610

PRIORITY APPLN. INFO.:

DE 2001-10111058	A	20010308
US 2001-281653P	P	20010405
DE 2000-10054042	A	20001031
US 2000-253613P	P	20001128
DE 2000-10062712	A	20001215
DE 2000-10063957	A	20001220
US 2000-257220P	P	20001221
US 2000-257221P	P	20001221
DE 2001-10110772	A	20010307
DE 2001-10113366	A	20010320
US 2001-281857P	P	20010405
US 2001-281874P	P	20010405
DE 2001-10138272	A	20010810
US 2001-314599P	P	20010824
US 2001-7182	B1	20011019
US 2001-86145	B1	20011019
US 2001-27662	B1	20011220
DE 2002-10206505	A	20020216
US 2002-92116	A1	20020306
US 2002-93240	B1	20020307
US 2002-100659	A1	20020318

US 2002-369213P	P	20020401
US 2003-360064	A2	20030207
US 2003-413065	B2	20030414
US 2003-419358	A1	20030421
US 2003-613783	A2	20030703
US 2004-763894	A2	20040123
US 2004-775901	A2	20040210
US 2004-776757	A2	20040211
US 2004-824391	A2	20040414
AU 2006-202723	A3	20060626

OTHER SOURCE(S): MARPAT 137:346202

IT 415916-92-6P 415917-07-6P 457910-79-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)

RN 415916-92-6 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl- (CA INDEX NAME)



RN 415917-07-6 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 457910-79-1 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(2-hydroxyethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl- (CA INDEX NAME)



IT 457910-81-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)
RN 457910-81-5 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl- (CA INDEX NAME)



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
TI Inhalant compositions containing anticholinergics and NK1 receptor antagonists
AB The invention relates to drug compns. based on anticholinergics and on NK1 receptor antagonists, to methods for their prodn., and to their use as inhalants for the treatment of respiratory tract diseases. Synthesis of NK1 receptor antagonists from the group of bis-trifluoromethyl-phenyl-piperidine derivs. are described. The products are used in suspension aerosols. Thus a compn. contained (wt./wt.%): tiotropium bromide 0.015; NK1 receptor antagonist 0.066; soy lecithin 0.2; TG11: TG12 = 2:3 to 100.

ACCESSION NUMBER:	2002:695760 CAPLUS
DOCUMENT NUMBER:	137:237717
TITLE:	Inhalant compositions containing anticholinergics and NK1 receptor antagonists
INVENTOR(S):	Meade, Christopher John Montague; Pairet, Michel; Pieper, Michael Paul
PATENT ASSIGNEE(S):	Boehringer Ingelheim Pharma K.-G., Germany
SOURCE:	PCT Int. Appl., 42 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	19
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069944	A2	20020912	WO 2002-EP1987	20020226

WO 2002069944 A3 20031002
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
DE 10111058 A1 20020912 DE 2001-10111058 20010308
CA 2439915 A1 20020912 CA 2002-2439915 20020226
AU 2002251010 A1 20020919 AU 2002-251010 20020226
EP 1370293 A2 20031217 EP 2002-719915 20020226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004519484 T 20040702 JP 2002-569121 20020226
MX 2003PA08051 A 20031204 MX 2003-PA8051 20030905
AU 2006202723 A1 20060713 AU 2006-202723 20060626
AU 2006202723 B2 20080626
AU 2008202554 A1 20080703 AU 2008-202554 20080610
PRIORITY APPLN. INFO.: DE 2001-10111058 A 20010308
EP 2001-200657 A 20010223
AU 2002-308306 A3 20020222
WO 2002-EP1987 W 20020226
AU 2006-202723 A3 20060626

OTHER SOURCE(S): MARPAT 137:237717

IT 415916-92-6P 415917-07-6P 457910-79-1P
457911-01-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhalant compns. contg. anticholinergics and NK1 receptor antagonists)

RN 415916-92-6 CAPLUS

CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl- (CA INDEX NAME)



RN 415917-07-6 CAPLUS

CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 457910-79-1 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(2-hydroxyethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl- (CA INDEX NAME)



RN 457911-01-2 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 415916-92-6
CMF C28 H35 F6 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

IT 457910-81-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
RN 457910-81-5 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl- (CA INDEX NAME)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
TI 4-Aminopiperidinylacetamides as neurokinin antagonists
GI



I

AB Title compds. I [R1 = (CH2)3OH, CH2CH(OH)CH2OH, cycloalkylmethyl; R2 = H, alkyl, hydroxyalkyl, CH2CH(OH)CH2OH, cycloalkylmethyl; R3 = (un)substituted Ph; R4 = H, alkyl, cycloalkyl, CH2CO2H, CH2CONH2. OH, phenylalkyl; Ar = (un)substituted Ph] were prepd. Thus, 1-benzyl-4-piperidinone was treated with H2N(CH2)3OH, N-methylated, debenzylated, and treated with 3,5-(F3C)2C6H3CH2CH2NMeCOCHPhO3SMe to give I [R1 = (CH2)3OH, R2 = R3 = Me, R4 = 3,5-(F3C)2C6H3CH2CH2]. At 0.2 .mu.Mol/kg iv in guinea pigs this compd. was effective in lowering blood pressure for > 360 min.

ACCESSION NUMBER:	2002:314907 CAPLUS
DOCUMENT NUMBER:	136:340590
TITLE:	4-Aminopiperidinylacetamides as neurokinin antagonists
INVENTOR(S):	Dollinger, Horst; Esser, Franz; Jung, Birgit; Schromm, Kurt; Speck, Georg
PATENT ASSIGNEE(S):	Boehringer Ingelheim Pharma K.-G., Germany
SOURCE:	PCT Int. Appl., 36 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032865	A1	20020425	WO 2001-EP11906	20011016

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10051320	A1	20020425	DE 2000-10051320		20001017
AU 2002023617	A	20020429	AU 2002-23617		20011016
US 20020147219	A1	20021010	US 2001-981025		20011016
US 6747044	B2	20040608			
CA 2426221	A1	20030417	CA 2001-2426221		20011016
EP 1328516	A1	20030723	EP 2001-987744		20011016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004514658	T	20040520	JP 2002-536049		20011016
MX 2003PA03334	A	20041202	MX 2003-PA3334		20030415
PRIORITY APPLN. INFO.:			DE 2000-10051320	A	20001017
			US 2000-250541P	P	20001201
			WO 2001-EP11906	W	20011016

OTHER SOURCE(S): MARPAT 136:340590

IT 415917-04-3P 415917-07-6P 502422-75-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-aminopiperidinylacetamides as neurokinin antagonists)

RN 415917-04-3 CAPLUS

CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(2-hydroxyethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 415917-07-6 CAPLUS

CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 502422-75-5 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl-, (2E)-2-butenedioate (2:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 415916-92-6
CMF C28 H35 F6 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 415917-12-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-aminopiperidinylacetamides as neurokinin antagonists)
RN 415917-12-3 CAPLUS
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT